Ligand Pharmaceuticals has been granted a patent for compounds and methods involving imidazole-fused heterocycle amines. The disclosed embodiments include compounds useful for treating leukemia and hematopoietic disorders. GlobalData’s report on Ligand Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Ligand Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Ligand Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Ligand Pharmaceuticals's grant share as of February 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.

The granted patent (Publication Number: US11858938B2) discloses a compound of Formula (III) along with various specific embodiments and variations. The compound described in the claims includes different substituents such as hydrogen, heterocyclylalkyl groups like pyrrolidyl-CH2-, piperidinyl-CH2-, and morpholine-CH2-, as well as heteroaryl groups like pyridyl, pyrazinyl, pyridazinyl, or pyrimidyl. The patent also covers pharmaceutical compositions containing the compound of claim 1, or its pharmaceutically acceptable derivatives, along with suitable carriers and excipients for effective delivery.

Furthermore, the patent claims encompass a range of options for the substituents R1, R2, R3, R4a, R5a, and R5b, providing flexibility in the design and synthesis of the compound. The disclosed compounds and compositions are intended for pharmaceutical applications, indicating potential therapeutic uses based on the structure and properties of the compound. The patent's detailed description of the compound's structure and variations, along with the inclusion of pharmaceutical compositions, highlights the innovation and potential utility of the disclosed invention in the field of drug development and treatment methodologies.

To know more about GlobalData’s detailed insights on Ligand Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies